The Current Status of Multidrug-Resistant Tuberculosis in One Tertiary Hospital in Busan, 2005~2009.
10.4046/trd.2011.71.2.120
- Author:
Neul Bom YOON
1
;
Sung Woo LEE
;
Su Min PARK
;
Il Hwan JEONG
;
So Young PARK
;
Song Yee HAN
;
Yu Rim LEE
;
Jin Kyu JUNG
;
Joon Mo KIM
;
Su Young KIM
;
Soo Jung UM
;
Soo Keol LEE
;
Choonhee SON
;
Young Hee HONG
;
Ki Nam LEE
;
Mee Sook ROH
;
Kyeong Hee KIM
Author Information
1. Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea. sjum@dau.ac.kr
- Publication Type:Original Article
- Keywords:
Prevalence;
Tuberculosis, Multidrug-Resistant
- MeSH:
Drug Resistance;
Drug Resistance, Multiple;
Ethambutol;
Humans;
Isoniazid;
Logistic Models;
Mycobacterium;
Prevalence;
Recurrence;
Retrospective Studies;
Rifampin;
Risk Factors;
Streptomycin;
Tertiary Care Centers;
Treatment Failure;
Tuberculosis;
Tuberculosis, Multidrug-Resistant;
Tuberculosis, Pulmonary
- From:Tuberculosis and Respiratory Diseases
2011;71(2):120-125
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Although the prevalence of pulmonary tuberculosis has progressively decreased all over the world, drug-resistant tuberculosis is major obstacle in treating tuberculosis. This study was performed to examine the current prevalence and risk factors of drug resistant tuberculosis in a single tertiary hospital in Busan, Korea. METHODS: We enrolled 367 patients with active pulmonary tuberculosis on a retrospective basis who had undergone mycobacterium culture and drug sensitivity tests between January 2005 and December 2009. We analyzed all clinical and radiographic parameters to find predictors related to drug resistant tuberculosis. RESULTS: At least one incident of drug resistance was found in 75 (20.4%) patients. Isoniazid (18.8%) was the most frequent resistant drug, followed by rifampin (10.9%), ethambutol (7.1%), streptomycin (4.9%), and fluoroquinolone (2.7%). Resistance to second-line drugs was found in 37 (10.1%) patients. Multidrug resistance and extensively drug resistance was evident in 39 (10.6%) and 4 (1.1%) patients, respectively. Using multiple logistic regression analysis, history of previous treatment including relapse (odd ratio [OR], 11.3; 95% confidence interval [CI], 4.92~26.08; p<0.01), treatment failure (OR, 24.1; 95% CI, 5.65~102.79; p<0.01) and an age of below 46 years-old (OR, 3.8; 95% CI, 1.62~8.65; p<0.01) were found to be independent predictors of multidrug resistant tuberculosis. CONCLUSION: We found that the prevalence of drug resistant tuberculosis was considerably high. A careful consideration for possible drug resistant tuberculosis is warranted in patients with a history of previous treatment or for younger patients.
